Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?
- 1 May 2007
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Pharmacotherapy
- Vol. 8 (7), 957-964
- https://doi.org/10.1517/14656566.8.7.957
Abstract
Indinavir is one of four first-generation HIV-protease inhibitors and was the most popular amongst them in the late 1990s. It was initially licensed for use alone, given three times daily, administered away from meals and together with at least 1.5 litres of fluid per day. In clinical practice, it became common for clinicians to prescribe it with a ritonavir pharmacokinetic ‘boost’ to remove the food restriction, reduce the pill burden and enable a more convenient twice-daily dosing schedule. However, at a ritonavir-boosted dosing schedule of indinavir/ritonavir 800/100 mg b.i.d., the regimen proved toxic and poorly tolerable, and its use diminished as newer, better tolerated PIs became available. Recent research has suggested that ritonavir-boosted indinavir administered at lower doses, particularly indinavir/ritonavir 400/100 mg b.i.d., retains potency and is considerably less toxic. As a result, there is interest in its application in resource-constrained settings.Keywords
This publication has 31 references indexed in Scilit:
- Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavirPharmacogenetics and Genomics, 2006
- Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerabilityJournal of Antimicrobial Chemotherapy, 2005
- Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice dailyHIV Medicine, 2005
- Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 TrialThe Journal of Infectious Diseases, 2003
- Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patientsJournal of Antimicrobial Chemotherapy, 2003
- Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patientsAIDS, 2003
- Risk factors for indinavir-related renal colic in HIV patientsAIDS, 2002
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Influence of Environmental Temperature on Incidence of Indinavir‐Related NephrolithiasisClinical Infectious Diseases, 1999
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996